Data-driven subphenotyping of severe ARDS patients requiring VV-ECMO
By
Micha Landoll
Stephan Strassmann
Wolfram Windisch
Ulrich Steinseifer
Andreas Schuppert
Michael Neidlin
Christian Karagiannidis
July 3, 2026
Clinical Scorecard: Identification of Distinct Subphenotypes in Severe ARDS Patients Undergoing VV-ECMO Using Data-Driven Approaches
At a Glance
Category Detail
Condition Acute Respiratory Distress Syndrome (ARDS) Key Mechanisms Inflammation, coagulation, kidney/liver function, mechanical ventilation parameters Target Population Adult patients with ARDS treated with VV-ECMO Care Setting Intensive Care Unit (ICU)
Key Highlights
Study analyzed 598 ARDS patients treated with VV-ECMO. Distinct subphenotypes identified based on inflammation and organ function. Survival rates varied significantly among identified clusters. Multi-organ dysfunction correlated with longer ICU stays. Subphenotype-based stratification may enhance risk management. Guideline-Based Recommendations
Diagnosis
Use Berlin definition criteria for ARDS diagnosis. Management
Consider subphenotype characteristics for individualized treatment strategies. Monitoring & Follow-up
Monitor key parameters such as procalcitonin, creatinine, and coagulation markers. Risks
High mortality rates exceed 50% in severe ARDS patients requiring VV-ECMO. Patient & Prescribing Data
Patients with severe ARDS requiring VV-ECMO.
Renal, hepatic, and inflammatory dysfunctions are critical for survival outcomes.
Clinical Best Practices
Utilize data-driven approaches for identifying ARDS subphenotypes. Implement personalized treatment based on identified subphenotypes. Regularly assess and adjust therapy based on patient response and clinical parameters. Related Resources & Content
